Measuring HRT Response in Clinical Practice: Why Glycans Beat Hormone Snapshots

Hormone tests capture a single moment, whereas glycan testing captures the biological trend. Blood levels of estrogen, progesterone, and follicle-stimulating hormone (FSH, a hormone that rises as ovarian function declines) can shift within the same day, making a single blood draw an unreliable way to judge whether hormone replacement therapy (HRT) is actually working. IgG glycosylation, the sugar structures attached to immune antibodies, offers clinicians a stable, cumulative readout of how the immune system is responding to hormonal change over months, not hours.

For clinicians managing perimenopause and menopause, that difference matters clinically, not just conceptually. To see how this applies across practice settings, read our guide, GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

Why do hormone blood tests give an incomplete picture during perimenopause?

Hormone blood tests measure estrogen, progesterone, and FSH at a single point in time, and these levels can fluctuate dramatically, sometimes daily, during perimenopause. This variability leaves both patients and clinicians without a reliable way to judge where a woman actually stands or whether a treatment is helping. Glycans offer a different kind of signal: they provide an integrated readout of how the immune system has responded to hormonal change over an extended period, rather than a single fluctuating number. For a clinician deciding whether to adjust an HRT dose, this cumulative signal is more actionable than a hormone level that may look different on a different day.

What does GlycanAge actually measure in the context of menopause and HRT?

GlycanAge measures glycans, the sugar molecules attached to antibodies, which reflect systemic inflammation and immune function, two of the central drivers of biological aging. Estrogen decline during menopause dysregulates IgG glycosylation, the process controlling which glycan structures attach to immune antibodies, reducing anti-inflammatory glycans while increasing pro-inflammatory ones. This shift can raise GlycanAge, a person's biological age as measured through glycans, by over a decade during the menopause transition. Because this decline is driven by immune imbalance and not estrogen deficiency alone, GlycanAge reflects whether a treatment plan, whether estrogen-focused or broader, is restoring a more youthful glycan profile.

How much can HRT actually change a patient's GlycanAge?

Well-managed HRT protocols are associated with biological age reductions of 5 to 25 years in clinical testing, reflected in glycan shifts such as increased galactosylation (the addition of a sugar called galactose, associated with anti-inflammatory activity) and increased sialylation (a related anti-inflammatory glycan modification). In a placebo-controlled, randomized trial conducted by GlycanAge, suppression of gonadal hormones in healthy premenopausal women caused a marked increase in biological age, while estradiol add-back therapy prevented that increase entirely, confirming estrogen's protective role in maintaining a youthful glycan profile.

"Women who were deprived of their sex hormones, placed into a state resembling menopause without any hormonal treatment, aged an average of nine years in just six months, with some individuals aging as much as fifteen years."

— Dr. Julija Jurić, Lead Author, Genos Glycoscience Research Laboratory

Separately, one 55-year-old patient at Raffaele Medical who switched from oral estrogen-progesterone therapy to a bioidentical estradiol cream saw her GlycanAge fall by 10 years over 12 months, a change that was not evident from her symptoms alone. The extent of benefit varies by formulation, dosage, and individual response, and results must always be interpreted in clinical context.

When should a clinician run a baseline GlycanAge test?

A baseline GlycanAge test should be run before initiating HRT, giving the clinician a reference point against which to measure treatment response. Clinical assessment protocols recommend suspecting perimenopause or menopause, and considering a baseline test, in women aged 40 to 55 with cycle irregularity, vasomotor symptoms such as hot flashes and night sweats, recurrent illness or poor injury healing, or sleep and mood disturbance, even when GlycanAge is elevated relative to chronological age without other symptoms present. If a pre-menopausal GlycanAge result is available, it should be used as the individual benchmark going forward. At Raffaele Medical, every patient is tested at baseline before any hormone therapy is prescribed, precisely because traditional lab tests fluctuate too much to establish true cumulative hormone exposure.

How often should GlycanAge be retested once HRT starts?

Monitoring effectiveness at 3- to 4-month intervals is the standard protocol for tracking HRT response through GlycanAge, since immune and glycan changes driven by pharmaceutical interventions are typically observable within this window. Some clinical workflows retest sooner: at Raffaele Medical, the test is repeated after a couple of weeks on therapy, and a lack of improvement in glycan results signals the need for dose adjustments. Across the clinic's patient population, this retest-and-adjust approach has contributed to more than 1,500 cumulative years of reduced biological age. Rising GlycanAge values on a retest may indicate suboptimal dosing and warrant a formulation or dose review.

What does an elevated or improving GlycanAge result actually mean for HRT titration?

An elevation of more than 9 years above chronological age is interpreted as accelerated immune aging in the context of perimenopause and menopause assessment. Optimized estradiol therapy, calibrated to restore hormonal balance rather than simply raise hormone levels, can produce a 10 to 15 year improvement in GlycanAge, with research showing an average improvement of 15 years when hormonal balance, not just hormone levels, is properly restored. A lack of improvement, or unexpected deterioration, in glycan results signals the need for dose adjustment, a change in formulation, or a broader evaluation of lifestyle and metabolic factors, rather than assuming the current protocol is working. This makes GlycanAge an objective support for titration decisions, distinct from relying on symptom relief alone.

Is HRT response only about estrogen, or does GlycanAge capture more than that?

GlycanAge reflects the combined influence of estrogen, progesterone, androgens, and adrenal hormones on immune function, not estrogen alone. Progesterone, which can decline earlier due to irregular ovulation, has distinct anti-inflammatory and neuroprotective effects, and its absence can push glycan profiles toward inflammation even when estradiol levels look adequate on a blood test. Formulation, route of administration, and dosage all influence hormonal balance and the downstream glycan biology that GlycanAge captures. This is why, in some patients, estrogen therapy alone restores a youthful glycan profile, while in others, optimizing progesterone, androgen support, stress regulation, or metabolic health proves equally critical.

"For the first time, we can prove the systemic benefits of HRT with objective data, and that changes the conversation from short-term relief to long-term health and longevity."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical, New York City

Why is glycan testing better suited to tracking HRT than repeated hormone panels?

Glycan testing provides an integrated measure of cumulative hormonal and metabolic influence, capturing long-term biological response rather than the day-to-day variability seen in blood hormone levels. Hormone panels answer "what is the level right now," while GlycanAge answers "how has the immune system responded over time," which is the more clinically useful question when deciding whether a therapy is working. This distinction matters most in HRT titration, where dose and formulation changes need a stable signal to be judged against, not a fluctuating one. For clinicians, this turns HRT management from a process of adjusting to symptoms into a process of adjusting to measured biology.

Clinicians managing perimenopause, menopause, or broader hormone optimization can use GlycanAge to baseline patients before treatment, guide titration decisions with a stable biological signal, and demonstrate measurable outcomes to patients over time. Visit the Healthcare Providers page to see how to integrate GlycanAge into an HRT protocol, or view a sample report to see what a patient's glycan indexes and disease-association data look like in practice.

Give your HRT patients an objective way to see if their therapy is working, not just how they feel about it.

Explore GlycanAge for Providers →